Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Heron Therapeutics (HRTX) Enterprise Value (2016 - 2026)

Heron Therapeutics filings provide 16 years of Enterprise Value readings, the most recent being -$30.0 million for Q1 2026.

  • On a quarterly basis, Enterprise Value rose 15.85% to -$30.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$30.0 million, a 15.85% increase, with the full-year FY2025 number at -$29.6 million, up 16.38% from a year prior.
  • Enterprise Value hit -$30.0 million in Q1 2026 for Heron Therapeutics, down from -$29.6 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$29.3 million in Q3 2025 to a low of -$121.7 million in Q3 2022.
  • Median Enterprise Value over the past 5 years was -$40.6 million (2025), compared with a mean of -$52.4 million.
  • Biggest five-year swings in Enterprise Value: surged 84.78% in 2022 and later crashed 102.58% in 2024.
  • Heron Therapeutics' Enterprise Value stood at -$71.0 million in 2022, then rose by 19.66% to -$57.0 million in 2023, then surged by 37.96% to -$35.4 million in 2024, then increased by 16.38% to -$29.6 million in 2025, then dropped by 1.29% to -$30.0 million in 2026.
  • The last three reported values for Enterprise Value were -$30.0 million (Q1 2026), -$29.6 million (Q4 2025), and -$29.3 million (Q3 2025) per Business Quant data.